Replies to post #405863 on Anavex Life Sciences Corp (AVXL)

[Anshu2]

Irrespective, that means that the trial P2b/3 is not pivotal. In that case — P3 start is much more important than P2b/3 full results. In particular, I hope the upcoming P3 plan is explicitly approved by FDA — including the endpoints, dosing regimen/titrations, etc etc.

When would P3 start? 2024? Or 2025? I’m presuming 2023 is beyond hopes

[Investor2014]

Not so long ago being sceptical of more data for the 12th Jan JPM presentation was regarded pessimistic. Soon that will be two months ago.